1 - 4 of 4 results
1 CME CREDIT

Cardiology expert, Christian Ruff, MD, MPH & primary care specialist, Elaine Hylek, MD, MPH will review the latest research and recommendations for patients with polyvascular disease. The faculty also will discuss patient cases that cover long-term atherothrombotic risks, chronic coronary artery disease (CAD)/peripheral artery disease (PAD), benefits of direct oral anticoagulants (DOACs), and considerations for the multidisciplinary team.


group overviewing case
1 CME CREDIT

Challenging Cases in Primary Care

1.00 CME/MOC
1.00 AANP | 0.40 Pharmacology

In this session, the speaker will discuss some challenging diagnostic cases that primary care practitioners may face in their practice. These cases will feature interpretation of laboratory and imaging studies as well as encounters with rare diseases and conditions. You will learn which aspects of the history and physical exam are most useful to establish certain diagnoses, increase your awareness of certain uncommon but “can’t miss” diagnoses, and become familiar with clinical decision aids that improve diagnostic accuracy for certain common diagnoses.


lipoprotein cell close up

Lipoprotein(a) Learning Module

An Adaptive Learning Experience Sponsored by Novartis Pharmaceuticals Corporation; Not for CME/CE CreditThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

Lipoprotein(a) is a genetically determined LDL-C like particle that is uniquely proatherogenic, prothrombotic, and proinflammatory. While emerging therapies are on the horizon, there are no current FDA approved medicinal treatment options for Lp(a). Understanding the prevalence and need to test for Lp(a) will help your patients mitigate potential cardiovascular risks via lifestyle modification and informing clinical practice. This interactive module will cover: • The differences between LDL-C and Lp(a) • Testing and incidence of Lp(a), as well as associated diseases • Cardiovascular risk and risk-enhancing factors that can lead to cardiovascular events • Lifestyle management and risk factor mitigation


lipoprotein cell close up

Lipoprotein(a) Learning Module

An Adaptive Learning Experience Sponsored by Novartis Pharmaceuticals Corporation; Not for CME/CE CreditThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

Lipoprotein(a) is a genetically determined LDL-C like particle that is uniquely proatherogenic, prothrombotic, and proinflammatory. While emerging therapies are on the horizon, there are no current FDA approved medicinal treatment options for Lp(a). Understanding the prevalence and need to test for Lp(a) will help your patients mitigate potential cardiovascular risks via lifestyle modification and informing clinical practice. This interactive module will cover: • The differences between LDL-C and Lp(a) • Testing and incidence of Lp(a), as well as associated diseases • Cardiovascular risk and risk-enhancing factors that can lead to cardiovascular events • Lifestyle management and risk factor mitigation